What AI says about tofersen (QALSODY)

QALSODY (tofersen) is the first FDA-approved treatment for adults with amyotrophic lateral sclerosis (ALS) who have a mutation in the SOD1 gene. It targets a genetic cause of ALS and was approved under accelerated approval based on reduction in neurofilament light chain (NfL) levels in the blood.